EMB Consultancy

INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.

Retrieved on: 
星期四, 九月 7, 2023
Cognition, EMB Consultancy, Food, Medicine, Multiple sclerosis, Eye, MS, Tablet, Biomarker, HIV disease progression rates, Novartis, Machine learning, Algorithm, Neuroscience, Entrepreneurship, AI, FDA, GMB (trade union), Pharmaceutical industry, Frontiers, Neurology

MONTREAL, Sept. 7, 2023 /PRNewswire/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Key Points: 
  • MONTREAL, Sept. 7, 2023 /PRNewswire/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).
  • This commercial agreement follows the favorable results of the observational trial involving people living with multiple sclerosis (MS).
  • The peer reviewed performance data, which are the subject of a publication in Frontiers in Neurology, can be accessed here: https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract .
  • Novartis has recognized Innodem's scalable technology and pending its regulatory clearance, intends to help us bring it to the mainstream with this collaboration," said Marc Reeves, Co-Founder and Chief Business Officer, Innodem Neurosciences.

INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.

Retrieved on: 
星期四, 九月 7, 2023
Cognition, EMB Consultancy, Food, Medicine, Multiple sclerosis, Eye, MS, Tablet, Biomarker, HIV disease progression rates, Novartis, Machine learning, Algorithm, Neuroscience, Entrepreneurship, AI, FDA, GMB (trade union), Pharmaceutical industry, Frontiers, Neurology

MONTREAL, Sept. 7, 2023 /PRNewswire/ -- Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Key Points: 
  • MONTREAL, Sept. 7, 2023 /PRNewswire/ -- Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).
  • This commercial agreement follows the favorable results of the observational trial involving people living with multiple sclerosis (MS).
  • The peer reviewed performance data, which are the subject of a publication in Frontiers in Neurology, can be accessed here: https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract .
  • Novartis has recognized Innodem's scalable technology and pending its regulatory clearance, intends to help us bring it to the mainstream with this collaboration," said Marc Reeves, Co-Founder and Chief Business Officer, Innodem Neurosciences.

Supplier.io Enters First-Ever Strategic Partnership with MSDUK to Expand Global Diverse Supplier Database

Retrieved on: 
星期四, 四月 27, 2023
Social responsibility, Supplier, Database, ESG, Software as a service, Partnership, EMB Consultancy, Food industry

CHICAGO, April 27, 2023 /PRNewswire/ -- Supplier.io, the leading data, analytics and SaaS provider of supplier diversity management solutions, today is proud to announce a partnership with Minority Supplier Development U.K. (MSDUK), the U.K.'s leading supplier diversity advocacy organization, to augment Supplier.io's database of more than two million diverse suppliers with MSDUK's database of certified U.K. businesses. Supplier.io is the only company that currently offers complete MSDUK certified diverse supplier data as part of its database.

Key Points: 
  • Supplier.io is the only company that currently offers complete MSDUK certified diverse supplier data as part of its database.
  • This alliance aims to advance diversity in the global supply chain, promoting equal opportunity and inclusion for underrepresented suppliers globally.
  • According to the 2022 State of Supplier Diversity report , 73% of supply chain and procurement leaders are challenged in finding qualified diverse suppliers.
  • Supplier.io solves a crucial challenge to help supply chain teams find certified diverse suppliers across the globe effortlessly.

Black Knight's First Look: Expanded and Enhanced Market Data Shows Mortgage Delinquency Improvement Across the Board in January, Uptick in Foreclosure Starts

Retrieved on: 
星期五, 二月 24, 2023
Blog, BKI, Housing, Delinquent, NYSE, Hurricane Ian, Black Knight, Black Knight, Inc., Table, Face, EMB Consultancy, Bank, Self storage, Mail, Real estate

Loan-level detail on more than 200M active and historical mortgages has already made McDash the industry's leading repository of servicer-contributed performance data.

Key Points: 
  • Loan-level detail on more than 200M active and historical mortgages has already made McDash the industry's leading repository of servicer-contributed performance data.
  • "Mortgage data in McDash comes from a wide range of servicers, including both Black Knight MSP servicing clients as well as those using other servicing systems of record.
  • Foreclosure starts rose 17% in the month to 33K, marking the fourth consecutive increase, but remain 37% below pre-pandemic levels.
  • Our role as a public provider of objective and unvarnished housing and mortgage market data and analysis is something we take very seriously.

Rogue Station Companies/Everdime, Inc. Acquires Show Homes Business and Intellectual Property

Retrieved on: 
星期三, 七月 6, 2022
Bitcoin, Acquisition, Non-fungible token, CEO, GLOBE, Marketing, Company, U.S. Securities and Exchange Commission, Security (finance), Associate, Private Securities Litigation Reform Act, EMB Consultancy, Risk factor, DIY, Social media, OTC Markets Group, Cryptocurrency, Token

Sheridan, Wyoming, July 06, 2022 (GLOBE NEWSWIRE) -- Rogue Station Companies/Everdime, Inc. (OTC Pink: RGST) is pleased to announce that it has executed an agreement with Embeli & Associates to acquire Show Homes, and its intellectual property.

Key Points: 
  • Sheridan, Wyoming, July 06, 2022 (GLOBE NEWSWIRE) -- Rogue Station Companies/Everdime, Inc. (OTC Pink: RGST) is pleased to announce that it has executed an agreement with Embeli & Associates to acquire Show Homes, and its intellectual property.
  • ShowHomesHub.com aggregates IDX/MLS agents listings and in turn displays them beautifully, attracting more potential buyers to the agents listings.
  • In addition, DIY property sellers and renters can create a gorgeous listing website to showcase and market their property like a professional.
  • Sandor Miklos, CEO of Everdime stated: We are very excited about the acquisition of Show Homes Intellectual Property.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
Google Images, Magnetic resonance imaging, MRI, SPMS, Goto, De novo, Literature, Self-test of intelligence, EMB Consultancy, Sclerosis, Quality of life, Clinical trial, Algorithm, Neurodegeneration, Brain, Alzheimer's disease, EDSS, Multiple sclerosis, DC, Frontotemporal dementia, PPMS, Eye, RRMS, Eye movement, GMB (trade union), IVD, Robotics, MCRA, Elective surgery, McGill University, Partnership, General surgery, Spine, Consultant, Parkinson's disease, Neuroscience, Patient, Neurology, Industry, Urology, Minuteman Library Network, Biomarker, Contract research organization, CRO, Technology, HIV disease progression rates, HIPAA, Intelligence, Diagnosis, Medical device, CEO, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
CEO, Google Images, Consultant, Parkinson's disease, PPMS, Eye, Neuroscience, RRMS, Partnership, Magnetic resonance imaging, Eye movement, Patient, MRI, GMB (trade union), SPMS, Sclerosis, IVD, Quality of life, Neurology, Clinical trial, Robotics, MCRA, Algorithm, Goto, McGill University, Neurodegeneration, Brain, Elective surgery, Industry, Urology, De novo, Literature, Minuteman Library Network, Biomarker, Contract research organization, Alzheimer's disease, Self-test of intelligence, CRO, EDSS, General surgery, Multiple sclerosis, Technology, HIV disease progression rates, HIPAA, Intelligence, Spine, EMB Consultancy, Diagnosis, DC, Medical device, Frontotemporal dementia, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

Sammons Financial Group Announces Record Community-Giving in 2021

Retrieved on: 
星期一, 一月 31, 2022
Lifescape (magazine), Principal, View, Employee Stock Ownership Plan, Dinshaw Maneckji Petit, Organization, Legacy, House, ESOP, Employment, Housing, Color, Partnership, City, Disability in Canada, Health, Community foundation, Olympic Games, Love, Boulevard, Education, EMB Consultancy, Densho: The Japanese American Legacy Project, Birdy, Time, Industry, Multimedia, Sammons, Hunger, St. Anthony Hospital, Life, Big Brothers Big Sisters, Management, YWCA, United Way

"It's crucial for us to be part of the communities where we live and work," said Esfand Dinshaw, chairman and chief executive officer at Sammons Financial Group.

Key Points: 
  • "It's crucial for us to be part of the communities where we live and work," said Esfand Dinshaw, chairman and chief executive officer at Sammons Financial Group.
  • As an Employee Stock Ownership Plan (ESOP) owned company, Sammons Financial Group supports a broad range of local charitable organizations tackling issues and needs that employees are passionate about.
  • Sammons Financial Group has corporate locations in five cities each donating a portion of the total $3.75 million to local community partners.
  • A subsidiary of Sammons Enterprises, Inc. , Sammons Financial Group is privately owned with member companies that are among the most enduring and stable in the financial services industry.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.